Aktienanalyse zu Fortress Biotech Inc (FBIO)FBIOFortress Biotech Inc

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Fortress Biotech Inc (FBIO) is a good buy right now due to its current price of $1.93, which is significantly below the analyst price target of $5, indicating a potential upside of over 150%. Additionally, the stock has shown a recent positive trend with a 5-day change of +3.21%, suggesting a recovery momentum. However, investors should be cautious of the risk posed by the company's recent earnings report, which showed a net income of -$2.48 million in Q2 2026, indicating ongoing profitability challenges.

2 analysts cover FBIO: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.75.